MAZE · Categories · Coverage
MAZE - Analyst coverage initiated
Maze Therapeutics Inc. (MAZE) analyst coverage initiated - real-time wire coverage filtered to Coverage only.
Recent Coverage for MAZE
- Canaccord Genuity initiated coverage on Maze Therapeutics with a new price targetCanaccord Genuity initiated coverage of Maze Therapeutics with a rating of Buy and set a new price target of $75.00
- Citigroup initiated coverage on Maze Therapeutics with a new price targetCitigroup initiated coverage of Maze Therapeutics with a rating of Buy and set a new price target of $50.00
- Truist initiated coverage on Maze Therapeutics with a new price targetTruist initiated coverage of Maze Therapeutics with a rating of Buy and set a new price target of $68.00
- Mizuho initiated coverage on Maze Therapeutics with a new price targetMizuho initiated coverage of Maze Therapeutics with a rating of Outperform and set a new price target of $97.00
- Wells Fargo initiated coverage on Maze Therapeutics with a new price targetWells Fargo initiated coverage of Maze Therapeutics with a rating of Overweight and set a new price target of $55.00
- Raymond James initiated coverage on Maze TherapeuticsRaymond James initiated coverage of Maze Therapeutics with a rating of Outperform
- BTIG Research initiated coverage on Maze Therapeutics with a new price targetBTIG Research initiated coverage of Maze Therapeutics with a rating of Buy and set a new price target of $30.00
- H.C. Wainwright initiated coverage on Maze Therapeutics with a new price targetH.C. Wainwright initiated coverage of Maze Therapeutics with a rating of Buy and set a new price target of $34.00
- Wedbush initiated coverage on Maze Therapeutics with a new price targetWedbush initiated coverage of Maze Therapeutics with a rating of Outperform and set a new price target of $17.00